Dr. Strop has over 20 years of experience in multiple therapeutic areas focusing on improving disease understanding at the molecular level and translating this knowledge into novel therapies. He authored more than 70 publications and is an inventor on 19 patents. Dr. Strop joined Tallac in 2021 and works with the Research team toadvance a pipeline of novel Toll-like receptor agonist antibody conjugates towards clinical development. Previously, as Executive Director, BMS, Dr. Strop lead Redwood city Discovery Biotherapeutics group. His team formed close cross-functional partnerships to design, execute and advance projects focusing on next generation immuno-oncology and tumor microenvironment therapies. Prior to BMS, Dr. Strop was a Director of Biochemistry at Rinat/Pfizer where he developed and applied novel technologies for oncology including site-specific antibody drug conjugates and bispecifics. Dr. Strop received his Ph.D. from Caltech where he elucidated structural mechanism of mechanosensitive ion channels and completed his postdoc training at Stanford where he studied proteins involved in synaptic neurotransmission.